| Autor: |
Saydoff JA; Neuroscience Research, Wellstat Therapeutics Corporation, 930 Clopper Road, Gaithersburg, MD 20878, USA. jsaydoff@wellstattherapeutics.com, Garcia RA, Browne SE, Liu L, Sheng J, Brenneman D, Hu Z, Cardin S, Gonzalez A, von Borstel RW, Gregorio J, Burr H, Beal MF |
| Jazyk: |
angličtina |
| Zdroj: |
Neurobiology of disease [Neurobiol Dis] 2006 Dec; Vol. 24 (3), pp. 455-65. Date of Electronic Publication: 2006 Sep 29. |
| DOI: |
10.1016/j.nbd.2006.08.011 |
| Abstrakt: |
Previously, uridine pro-drug 2',3',5'-tri-O-acetyluridine (PN401) was shown to be protective in the mitochondrial complex II inhibitor 3-nitropropionic acid model of Huntington's disease (HD). In this study, PN401 increased survival and improved motor function on the rotarod in both R6/2 and N171-82Q polyglutamine repeat mouse models of HD. PN401 significantly decreased neurodegeneration in both the piriform cortex and striatum although PN401 decreased huntingtin protein aggregates only in the striatum. Cortical and striatal brain-derived neurotrophic factor (BDNF) protein levels were reduced in the +/- compared to the -/- N171-82Q mice and PN401 treatment significantly increased cortical BDNF in both +/- and -/- mice, but PN401 did not affect striatal BDNF. These results suggest that PN401 may have beneficial effects in the treatment of neurodegenerative diseases such as HD. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Full Text from ScienceDirect